Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
IC

NASDAQ · ICCM

IceCure Medical Ltd

Healthcare · Medical - Devices

$0.79

Up+$0.02 (+2.54%)

Updated Nov 5, 2026, 8:16 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.08M
P/E ratio
-2.85
Dividend yield
0.00%
52-week range
$0.22 – $9.54
Volume
43.42K
Avg. volume
1.17M

Price performance · ICCM

ICCM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

ICCM closed at $0.79 after 21 trading sessions, down 31.25% for the selected period.

Last close
$0.79
Period change
-31.25%
Period low
$0.77
Period high
$1.15
Daily close
View OHLC price history
ICCM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.81$0.8101$0.7775$0.790643.42K
Nov 3, 2026$0.8407$0.8407$0.75$0.771148.95K
Nov 2, 2026$0.896$0.899$0.833$0.842854.36K
Oct 30, 2026$0.94$0.951$0.8201$0.870150.26K
Oct 29, 2026$1.00$1.00$0.92$0.956756.71K
Oct 28, 2026$0.98$1.04$0.8445$0.977566.27K
Oct 27, 2026$1.04$1.09$1.00$1.0392.32K
Oct 26, 2026$1.00$1.05$0.9741$1.03103.79K
Oct 23, 2026$1.02$1.07$1.01$1.0142.35K
Oct 22, 2026$1.06$1.12$1.00$1.00168.57K
Oct 21, 2026$1.05$1.12$1.05$1.0892.75K
Oct 20, 2026$1.07$1.11$1.05$1.05104.34K
Oct 19, 2026$1.09$1.12$1.0304$1.08147.15K
Oct 16, 2026$1.05$1.10$1.03$1.06105.46K
Oct 15, 2026$1.04$1.07$1.0003$1.0493.7K
Oct 14, 2026$1.09$1.09$0.9601$1.04151.77K
Oct 13, 2026$1.11$1.13$1.0301$1.10262.6K
Oct 12, 2026$1.11$1.19$1.06$1.0879.05K
Oct 9, 2026$1.17$1.175$1.05$1.10124.73K
Oct 8, 2026$1.15$1.21$1.04$1.13326.81K
Oct 7, 2026$1.29$1.30$1.15$1.15355.46K

Latest ICCM news

The latest Smart Investors Daily articles mentioning ICCM.

Stock researchCompany · Overview

ICCM research

Overview

Company profile and research snapshot.

Company profile

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.38
Implied upside
—
Analysts
—
ICCM recent ratings
DateFirmRatingTarget
May 14, 2026Maxim GroupBuy—
Oct 7, 2025HC Wainwright & Co.Buy—
Aug 15, 2025HC Wainwright & Co.Buy—
May 29, 2025HC Wainwright & Co.Buy—
Mar 28, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has successfully completed the treatment of the first patient in its post-marketing study (the "ChoICE Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer.

Yahoo · Oct 20, 2026

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study (the "ChoICE Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By